These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 39400611)

  • 1. Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies.
    Kandav G; Chandel A
    Med Oncol; 2024 Oct; 41(11):275. PubMed ID: 39400611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR-T cell therapy: current limitations and potential strategies.
    Sterner RC; Sterner RM
    Blood Cancer J; 2021 Apr; 11(4):69. PubMed ID: 33824268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies.
    Liu Y; Peng C; Ahad F; Ali Zaidi SA; Muluh TA; Fu Q
    Recent Pat Anticancer Drug Discov; 2024; 19(5):557-572. PubMed ID: 38213150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advances in CAR-T Therapy.
    Ali MB
    Cancer Control; 2024; 31():10732748241263713. PubMed ID: 38910268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
    Hunter BD; Rogalski M; Jacobson CA
    Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
    [No Abstract]   [Full Text] [Related]  

  • 9. Future perspectives on engineered T cells for cancer.
    Posey AD; Young RM; June CH
    Trends Cancer; 2024 Aug; 10(8):687-695. PubMed ID: 38853073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR-T cell therapy: a game-changer in cancer treatment and beyond.
    Utkarsh K; Srivastava N; Kumar S; Khan A; Dagar G; Kumar M; Singh M; Haque S
    Clin Transl Oncol; 2024 Jun; 26(6):1300-1318. PubMed ID: 38244129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies.
    Ai K; Liu B; Chen X; Huang C; Yang L; Zhang W; Weng J; Du X; Wu K; Lai P
    J Hematol Oncol; 2024 Nov; 17(1):105. PubMed ID: 39501358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor (CAR) T-cell therapy: Harnessing extracellular vesicles for enhanced efficacy.
    Spokeviciute B; Kholia S; Brizzi MF
    Pharmacol Res; 2024 Oct; 208():107352. PubMed ID: 39147005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy.
    Wang Z; Zhou L; Wu X
    Oncol Res; 2024; 32(9):1479-1516. PubMed ID: 39220130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arming Vδ2 T Cells with Chimeric Antigen Receptors to Combat Cancer.
    Thomas P; Paris P; Pecqueur C
    Clin Cancer Res; 2024 Aug; 30(15):3105-3116. PubMed ID: 38747974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting.
    Sutherland AR; Owens MN; Geyer CR
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33007850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy.
    Huang Y; Li D; Qin DY; Gou HF; Wei W; Wang YS; Wei YQ; Wang W
    Gene Ther; 2018 Jun; 25(3):192-197. PubMed ID: 28820501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
    Jindal V; Arora E; Gupta S
    Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Car T Cells in Solid Tumors: Overcoming Obstacles.
    Rojas-Quintero J; Díaz MP; Palmar J; Galan-Freyle NJ; Morillo V; Escalona D; González-Torres HJ; Torres W; Navarro-Quiroz E; Rivera-Porras D; Bermúdez V
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.